The emerging role of cannabinoid neuromodulators in symptom management

被引：31

作者：

Davis, Mellar

Maida, Vincent

Daeninck, Paul

Pergolizzi, Joseph

机构：

[1] Cleveland Clin, Harry R Horvitz Ctr Palliat Med, Cleveland, OH 44195 USA

[2] William Osler Hlth Ctr, Toronto, ON, Canada

[3] Univ Toronto, Toronto, ON, Canada

[4] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada

[5] Univ Manitoba, Dept Family Med, Winnipeg, MB, Canada

[6] CancerCare Manitoba, Winnipeg, MB, Canada

[7] Winnipeg Reg Palliat Care Program, Winnipeg, MB, Canada

[8] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[9] Natl Inst Pain, COPE, New York, NY USA

[10] Naples Anesthesia & Pain Associates, Naples, FL USA

来源：

SUPPORTIVE CARE IN CANCER | 2007年 / 15卷 / 01期

关键词：

cannabinoids; chemotherapy-induced nausea and vomiting; CB1 and CB2 receptors; pain;

D O I：

10.1007/s00520-006-0180-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy. Discussion: The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain. Summary: The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.

引用

页码：63 / 71

页数：9

共 24 条

[1]

ABRAHM J, 2005, PHYS GUIDE PAIN SYMP

[2] Neuropharmacology of emesis and its relevance to anti-emetic therapy - Consensus and controversies [J].